These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 9469330)

  • 1. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
    Elkhuizen PH; van Slooten HJ; Clahsen PC; Hermans J; van de Velde CJ; van den Broek LC; van de Vijver MJ
    J Clin Oncol; 2000 Mar; 18(5):1075-83. PubMed ID: 10694560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
    Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
    Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic importance of thymidylate synthase expression in early breast cancer.
    Pestalozzi BC; Peterson HF; Gelber RD; Goldhirsch A; Gusterson BA; Trihia H; Lindtner J; Cortés-Funes H; Simmoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Allegra CJ; Johnston PG
    J Clin Oncol; 1997 May; 15(5):1923-31. PubMed ID: 9164203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer in young women: prognostic factors and clinicopathological features.
    Aryandono T; Harijadi ; Soeripto
    Asian Pac J Cancer Prev; 2006; 7(3):451-4. PubMed ID: 17059343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
    van Slooten HJ; Clahsen PC; van Dierendonck JH; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van de Velde CJ; van de Vijver MJ
    Br J Cancer; 1996 Jul; 74(1):78-85. PubMed ID: 8679463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
    Clahsen PC; van de Velde CJ; Julien JP; Floiras JL; Delozier T; Mignolet FY; Sahmoud TM
    J Clin Oncol; 1996 Mar; 14(3):745-53. PubMed ID: 8622020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
    Torrisi R; Bagnardi V; Rotmensz N; Scarano E; Iorfida M; Veronesi P; Luini A; Viale G; Santoro A; Colleoni M; Goldhirsch A
    Breast Cancer Res Treat; 2011 Apr; 126(2):431-41. PubMed ID: 21221766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
    Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
    Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
    Muss HB; Thor AD; Berry DA; Kute T; Liu ET; Koerner F; Cirrincione CT; Budman DR; Wood WC; Barcos M
    N Engl J Med; 1994 May; 330(18):1260-6. PubMed ID: 7908410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.